Hepatitis B virus resistance to nucleos(t)ide analogues.
about
Adefovir dipivoxil for adults with lamivudine-resistant chronic hepatitis B virus infectionA high level of mutation tolerance in the multifunctional sequence encoding the RNA encapsidation signal of an avian hepatitis B virus and slow evolution rate revealed by in vivo infectionGenetic variation of occult hepatitis B virus infectionEfficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-AnalysisLessons learnt over two decades of vaccination against hepatitis B in ItalyOverview of hepatitis B virus mutations and their implications in the management of infectionMicroRNAs as Important Players in Host-hepatitis B Virus InteractionsChange of strategies and future perspectives against hepatitis B virus recurrence after liver transplantationTherapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuckHepatitis B virus reverse transcriptase: diverse functions as classical and emerging targets for antiviral interventionViral quasispecies evolutionRoles of hepatocyte nuclear factors in hepatitis B virus infectionCurrent progress in the development of therapeutic vaccines for chronic hepatitis B virus infectionDetection and analysis of resistance mutations of hepatitis B virusDynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencingUltra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genomeThe hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymesAssociation of preexisting drug-resistance mutations and treatment failure in hepatitis B patientsComparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysisDifferential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virusPre-existing mutations in reverse transcriptase of hepatitis B virus in treatment-naive Chinese patients with chronic hepatitis BSubstitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug ResistanceStable Human Hepatoma Cell Lines for Efficient Regulated Expression of Nucleoside/Nucleotide Analog Resistant and Vaccine Escape Hepatitis B Virus Variants and Woolly Monkey Hepatitis B VirusHBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data.Novel natural mutations in the hepatitis B virus reverse transcriptase domain associated with hepatocellular carcinoma.Viral hepatitis and hepatocellular carcinoma: etiology and managementInduction of IFN-γ cytokine response against hepatitis B surface antigen using melittin.Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy.Clinical implications of hepatitis B virus mutations: recent advances.Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.Antiviral drug resistance as an adaptive processSupport of the infectivity of hepatitis delta virus particles by the envelope proteins of different genotypes of hepatitis B virusHepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activityVirologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated Lamivudine-resistant chronic hepatitis BVirologic and clinical characteristics of HBV genotypes/subgenotypes in 487 Chinese pediatric patients with CHBThe Role of Interferon in Hepatitis B Therapy.Detection of mixed populations of wild-type and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients.Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B virusesImpairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein and rescue by a novel glycosylation site.
P2860
Q24187530-B1281558-27D2-4995-A9F1-F9D265EDDC6BQ24606375-06C685D1-1633-4EF3-85B9-AEDE48FBAFBAQ26751031-90AA197E-6EE7-49FA-AD66-754EAAB4AF98Q26765932-C15023FA-8A8E-4702-81F8-6753CF2C84E7Q26770673-471D0CC9-725F-40F9-9D17-650A030352B7Q26772346-A71C135E-83AE-4059-964C-A8B8CFDF08BBQ26781737-26055ADF-E6CD-4E93-B32F-9D564BED13CEQ26784241-759DF288-502C-4117-ACE7-1060FC05CE6FQ26828598-889BC119-C6AE-4BA0-A9F8-187B4BBE57C2Q27013849-D1BF3BE4-72BE-4399-8D71-25732609C2C9Q27013917-CEFFF13B-30A8-4067-9ADF-2A2305029791Q28069574-BBF92BB9-3283-4C70-8D34-E3B8A7E7C0C5Q28076279-4EB4E3E3-DCAE-47A7-8CA6-1B9AEA18FB25Q28266666-8946082A-05E4-4CB4-A353-D948B65780F0Q28482355-5F9F1981-C1B4-4035-BB25-07B0FB737270Q28484005-E81B8DFE-84E7-402D-A839-594B13AC6D6BQ28485228-81EBB0A0-9439-4B26-8468-53FECEDD670CQ28535003-EEE67735-730A-497A-941C-B0E011E928FAQ28539472-BDE6F21D-A846-4D07-9595-E0C92ACA6164Q28542705-0E17425A-276F-4C17-88E2-458864004256Q28545179-F500B79A-81F6-44DC-81ED-EE3CB87E7FEDQ28547647-D89DB792-ABF5-4245-A24B-4DEB41F13280Q28551711-50D40655-DE7C-45ED-90AB-677BDB107DCFQ30741676-20E920BC-07AB-422C-B46C-D16F1FF31D50Q33553814-96929B67-B2D3-4FB3-8E8E-3D2A85F0EDDAQ33593219-FF8237E6-6638-4AE1-8881-58C79EF886E9Q33596807-548A9205-DA47-42A7-AACE-A2A0D934C9A1Q33627462-A79DEB96-11BA-468F-A90F-4AA5888AD0ACQ33801311-9091A389-B18D-49D0-9EE0-9ACF0D2A45D7Q33857643-A46B6549-6445-4281-A247-05F3CD636763Q33878407-3697813E-584F-4C4D-80E8-CB4F19E323C6Q33887785-F1DC27BE-C5F7-4ABF-96A1-5EABCAB703F8Q33911464-4D9E7806-6B61-4758-8E4A-3F5B58CAD072Q33918275-C5BD0D88-F2B6-464D-93A7-23C6393B9FEBQ34036239-0AB697A8-ACF8-4AEE-918C-AF14962AF6E6Q34154958-CE7C4D43-9DD9-4695-9F32-30DFF9DA3ECEQ34294342-73DB97A3-45CF-438D-AA05-C6376E70B53EQ34339613-D155A70E-E097-45BE-8F07-F3BFA1FBC230Q34407460-0F25E40A-032E-46BE-8AC2-DB2AF80BC675Q34416463-7C10AE89-E424-40C7-B2B1-D9C4D0E58EF6
P2860
Hepatitis B virus resistance to nucleos(t)ide analogues.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hepatitis B virus resistance to nucleos
@nl
Hepatitis B virus resistance to nucleos(t)ide analogues.
@en
type
label
Hepatitis B virus resistance to nucleos
@nl
Hepatitis B virus resistance to nucleos(t)ide analogues.
@en
prefLabel
Hepatitis B virus resistance to nucleos
@nl
Hepatitis B virus resistance to nucleos(t)ide analogues.
@en
P1433
P1476
Hepatitis B virus resistance to nucleos(t)ide analogues
@en
P2093
Stephen Locarnini
P304
1593-608.e1-2
P356
10.1053/J.GASTRO.2009.08.063
P407
P577
2009-09-06T00:00:00Z